Tourmaline Bio Inc

Tourmaline Bio Inc(TRML)财务数据

$47.980

0.000 (0.00%)收盘时

TRML 盈利能力与利润率

Evaluating the bottom line, Tourmaline Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -29.62%, provide a clear picture of how effectively TRML converts its operational activities into shareholder value.

TRML 同业对比

In the context of the broader market, TRML competes directly with industry leaders such as IMTX and ELVN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TRML's gross margin of N/A stands against IMTX's 100.00% and ELVN's N/A. Such benchmarking helps identify whether Tourmaline Bio Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2025Q2
YoY:
+18.22%
-25.97M
Operating Profit
FY2025Q2
YoY:
+32.05%
-23.09M
Net Income after Tax
FY2025Q2
YoY:
+32.35%
-0.90
EPS - Diluted
FY2025Q2
YoY:
+12.57%
-20.27M
Free Cash Flow

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始